Polycystic Kidney Disease (PKD): Management & Treatment Menu

Management of Polycystic Kidney Disease

Renal function usually remains normal until a polycystic kidney disease (PKD) patient reaches his or her forties. After that, the glomerular filtration rate (GFR–measurement of kidney function) declines steadily and irreversibly.

Since there are co-morbidities associated with (or caused by) PKD, treatment of them is part of a combined approach to global care.

Antihypertensives

Elevations in blood pressure are common in PKD patients, often before any decrease in kidney function. Due to the kidney’s role in blood pressure maintenance (the renin-angiotensin system), an angio-converting enzyme (ACE) inhibitor is used as an initial antihypertensive medication. When kidney failure progresses enough to cause a rise in serum creatinine, a beta blocker can be used to keep the blood pressure in normal range (for PKD patients, <130/80).

Low Sodium Diet

As PKD progresses, more sodium is excreted. This can be counteracted by decreasing sodium intake (dietary alteration–low sodium diet). Sodium restriction can slow the progress of PKD.

Statins for Dyslipidemia

Abnormal cholesterol and triglyceride levels should be treated aggressively with statin drugs, since chronic kidney disease is a major risk factor for coronary heart disease.

Vasopressin Antagonists

Vasopressin, also called “Anti-diuretic Hormone” (ADH), is a hypothalamic-made, pituitary-released hormone that controls water conservation in the kidney. Tolvaptan is a drug that suppresses vasopressin, and this action has been shown to slow down the growth of cysts and decrease the rate of GFR decline. Because it can cause liver toxicity and other side effects, however, it is primarily used in those who are high-risk for rapid PKD progression as determined by serial ultrasonography and GFR testing.

Increased Fluid Intake

Increasing fluids will suppress the natural vasopressin levels, which is a safer way than using tolvaptan, and therefore no risk to all patients with PKD. Increased fluids also dilutes minerals, decreasing the risk of stone formation.

Somatostatin Therapy

Natural somatostain inhibits the release of insulin, glucagon, and other pancreatic products. Octreotide, a somatostatin analog (mimics somatostatin), has been shown to decrease the accumulation of fluid in PKD cysts and slow the enlargement of the kidneys and liver that is part of the disease. It also slows GFR decline.

Treatment for ESRF

Eventually, end-stage renal failure requires another method to clear toxic wastes from the body other than the failed kidneys. This consists of dialysis, kidney transplant, or dialysis until a kidney is available for transplant.

Advertisement

Vascular Health Clinics is a regional multi-specialty program. Advertising on our site helps support our mission. We do not endorse non-Vascular Health Clinics products or services. Policy

© Copyright 2018 Vascular Health Clinics. All rights reserved.

This information is provided by Vascular Health Clinics and is not intended to replace the medical advice of your doctor or healthcare provider. Please consult your healthcare provider for advice about a specific medical condition.

Vascular Health Clinics News & More